WikiMD is the world's largest medical encyclopedia with
29,038 pages, 4,107,627 edits & 35,806,679 views.
Elotuzumab
Information about Elotuzumab
Elotuzumab is a humanized monoclonal antibody to cell surface receptor SLAMF7 which is used in combination with other antineoplastic agents in the therapy of multiple myeloma.
Liver safety of Elotuzumab
Elotuzumab has been implicated in rare instances of transient, marked serum enzyme elevations, but has not been linked to instances of clinically apparent liver injury with jaundice.
Mechanism of action of Elotuzumab
Elotuzumab (el" oh tooz' ue mab) is humanized IgG1 monoclonal antibody to the cell surface receptor signaling lymphocyte activation molecule family member 7 (SLAMF7), which is a transmembrane glycoprotein that is frequently overexpressed on multiple myeloma cells and is found normally on natural killer (NK) cells. The monoclonal antibody binds to the cell surface receptor and triggers cell apoptosis of cancer cells and activation of NK cells which may increase its antineoplastic activity. In preregistration trials, the addition of elotuzumab to lenalidomide and dexamethasone led to an increase in overall response rates and prolongation of progression-free survival.
FDA approval information for Elotuzumab
Elotuzumab was given accelerated approval for use in the United States in 2015. Current indications are as therapy of refractory multiple myeloma administered in combination with lenalidomide (or bortezomib) and dexamethasone or as monotherapy in patients who have failed at least three previous regimens. Elotuzumab is available as a powder for reconstitution in single use vials of 300 or 400 mg under the brand name Empliciti.
Dosage and administration for Elotuzumab
The recommended dose is 10 mg/kg intravenously every week for 2 cycles and every 2 weeks thereafter until disease progression or unacceptable toxicities occur.
Side effects of Elotuzumab
Premedication with dexamethasone, diphenhydramine, ranitidine and acetaminophen is recommended. side effects are common and can include infusion reactions, fatigue, diarrhea, constipation, anorexia, fever, cough, nasopharyngitis, peripheral neuropathy and pneumonia. Uncommon, but potentially severe adverse reactions include severe infusion reactions, bacterial infections and secondary malignancies.
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Cost and Coupons - Elotuzumab
- GoodRx compare cost & coupons for Elotuzumab
- Find the lowest cost of Elotuzumab
- Search for Coupons for Elotuzumab
Reviews for Elotuzumab
Learn more about Elotuzumab
- Dailymed label info
- Scientific articles
- Drug portal Elotuzumab
- toxicity info on Elotuzumab
- FDA Elotuzumab
Latest research (Pubmed)
External links
WikiMD needs you!
This WikiMD article Elotuzumab is a stub.
If you are a healthcare professional familiar with the topic Elotuzumab, or
A subject matter expert or authority on Elotuzumab, you can help us.
About | Mission | Paid editors welcome!
| Elotuzumab is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
|---|
| Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP* |
